Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats

Canadian Journal of Gastroenterology

Volumn 26, Issue 1, 2012, Pages 33-39

  Wengrower, Dov ^a   Zanninelli, Giuliana ^b   Latella, Giovanni ^b   Necozione, Stefano ^b   Metanes, Issa ^a   Israeli, Eran ^a   Lysy, Joseph ^a   Pines, Mark ^c   Papo, Orit ^a   Goldin, Eran ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c VOLCANI CENTER   (Israel)

Author keywords

Angiotensin II receptor antagonist; Experimental colitis; Fibrosis; Inflammatory bowel disease; Losartan; TGF 1; TNBS

Indexed keywords

LOSARTAN; LOSARTAN POTASSIUM; TRANSFORMING GROWTH FACTOR BETA1; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLORECTAL FIBROSIS; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VIVO STUDY; INFLAMMATION; INTESTINAL FIBROSIS; INTESTINE WALL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME;

EID: 84856403018     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/628268     Document Type: Article

References (78)

1. Geboes KP, Cabooter L, Geboes K. Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis. Acta Gastroenterol Belg 2000;63:371-6. (Pubitemid 32151021)
2. Van Assche G. Can we influence fibrosis in Crohn's disease? Acta Gastroenterol Belg 2001;64:193-6. (Pubitemid 32635408)
3. Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis 2004;10:55-60. (Pubitemid 38072447)
4. Rieder F, Brenmoehl J, Leeb S, Scholmerich J, Rogler G. Wound healing and fibrosis in intestinal disease. Gut 2007;56:130-9. (Pubitemid 46044899)
5. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007;102:439-48. (Pubitemid 46160558)
6. Rutgeerts P. Review article: Recurrence of Crohn's disease after surgery - the need for treatment of new lesions. Aliment Pharmacol Ther 2006;24 Suppl 3:29-32. (Pubitemid 44326416)
7. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-41. (Pubitemid 40139240)
8. Graham MF, Diegelmann RF, Elson CO, et al. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 1988;94:257-65. (Pubitemid 18054760)
9. Stallmach A, Schuppan D, Riese HH, Matthes H, Riecken EO. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology 1992;102:1920-1929
10. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts I. Paracrine cells important in health and disease. Am J Physiol Cell Physiol 1999;277:C1-19.
11. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts II. Intestinal subepithelial myofibroblasts. Am J Physiol Cell Physiol 1999;277:C183-201.
12. Pucilowska JB, Williams KL, Lund PK. Fibrogenesis IV. Fibrosis and inflammatory bowel disease: Cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000;279:G653-9.
13. Bonniaud P, Margetts PJ, Ask K, Flanders K, Gauldie J, Kolb M. TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol 2005;175:5390-5. (Pubitemid 41456425)
14. Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210. (Pubitemid 351160157)
15. Desmet VJ, Roskams T. Cirrhosis reversal: A duel between dogma and myth. J Hepatol 2004;40:860-67. (Pubitemid 38507370)
16. McKaig BC, Hughes k, Tighe PJ, Mahida YR. Differential expression of TGF-β isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002;282:C172-82.
17. Wells RG. Fibrogenesis V. TGF-b signaling pathways. Am J Physiol Gastrointest Liver Physiol 2000;279:G845-50.
18. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425:577-84. (Pubitemid 37280136)
19. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004;85:47-64. (Pubitemid 38703594)
20. Monteleone G, Pallone F, MacDonald TT. Smad7 in TGF-β-mediated negative regulation of gut inflammation. Trends Immunol 2004;25:513-7. (Pubitemid 39208348)
21. Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGF-β1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 2007;178:5859-5870 (Pubitemid 46674383)
22. Beddy D, Mulsow J, Watson RW, Fitzpatrick JM, O'Connell PR. Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg 2006;93:1290-6. (Pubitemid 44547031)
23. Mulsow JJ, Watson RW, Fitzpatrick JM, O'Connell PR. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg 2005;242:880-7.
24. Lawrance IC, Maxwell L, Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis 2001;7:226-36. (Pubitemid 32776516)
25. Di Mola F, Friess H, Scheuren A, et al. Transforming growth factor-βs and their signaling receptors are co expressed in Crohn's disease. Ann Surg 1999;229:67-75. (Pubitemid 30190382)
26. Mourelle M, Salas A, Guarner F, Crespo E, Garcia-Lafuente A, Malagelada JR. Stimulation of transforming growth factor beta-1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 1998;114:519-26. (Pubitemid 28141197)
27. Wengrower D, Zanninelli G, Pappo O, et al. Prevention of fibrosis in experimental colitis by captopril: The role of TGF-β1. Inflamm Bowel Dis 2004;10:536-45. (Pubitemid 39276460)
28. Vallance BA, Gunawan MI, Hewlett B, et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 2005;116-G128.
29. McKaig BC, McWilliams D, Watson SA, Mahida YR. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003;162:1355-60. (Pubitemid 36350679)
30. Dammeier J, Brauchle M, Falk W, Grotendorst GR, Werner S. Connective tissue growth factor: A novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int J Biochem Cell Biol 1998;30:909-22. (Pubitemid 28383395)
31. Di Mola FF, Di Sebastiano P, Gardini A, et al. Differential expression of connective tissue growth factor in inflammatory bowel disease. Digestion 2004;69:245-53. (Pubitemid 39140471)
32. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 1997;29:1947-58. (Pubitemid 27303099)
33. Fukuda N, Hu WY, Kubo A, et al. Angiotensin II upregulates transforming growth factor-beta I receptor on rat vascular smooth muscle cells. Am J Hypertens 2000;13:191-8. (Pubitemid 30125643)
34. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002;109:787-96. (Pubitemid 34263155)
35. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000;35:1078-84. (Pubitemid 30327261)
36. Uhal BD, Kim JK, Li X, Molina-Molina M. Angiotensin-TGF-beta1 crosstalk in human idiopathic pulmonary fibrosis: Autocrine mechanisms in myofibroblasts and macrophages. Curr Pharm Des 2007;13:1247-56. (Pubitemid 46739332)
37. Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: A balance of ACEs? Clin Sci (Lond) 2007;113:109-18. (Pubitemid 47237907)
38. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007;74:196-206.
39. Jaszewski R, Tolia V, Ehrinpreis MN, et al. Increased colonic mucosal angiotensin I and II concentration in Crohn's colitis. Gastroenterology 1990;98:1543-8. (Pubitemid 20158619)
40. Tzanidis A, Lim S, Hannan RD, See F, Ugoni AM, Krum H. Combined angiotensin and endothelin receptor blockade attenuate adverse cardiac remodeling post-myocardial infarction in the rat: Possible role of transforming growth factor beta1. J Mol Cell Cardiol 2001;35:969-81. (Pubitemid 32545331)
41. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverse myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001;103:789-91. (Pubitemid 32163874)
42. Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002;39:486-92. (Pubitemid 34194624)
43. Ishikawa A, Tanaka M, Ohta N, Ozono S, Kitamura T. Prevention of intestitial fibrosis of renal allograft by angiotensin II blockade. Transplant Proc 2006;38:3498-501. (Pubitemid 44908469)
44. Kellner D, Chen J, Richardson I, et al. Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. J Urol 2006;176:806-12. (Pubitemid 43927915)
45. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: Role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003;14:1132-44. (Pubitemid 36514656)
46. Königshoff M, Wilhelm A, Jahn A, et al. The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis. Am J Respir Cell Mol Biol 2007;37:640-50. (Pubitemid 350211634)
47. Yao HW, Zhu JP, Zhao MH, Lu Y. Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. Respiration 2006;73:236-42.
48. Yoshiji H, Kuriyama S, Yoshiji J, et al. Angiotensin II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-50. (Pubitemid 32927999)
49. Jonsson JR, Clouston AD, Ando Y, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001;121:148-55. (Pubitemid 32591525)
50. Ibañez P, Solis N, Pizarro M, et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2007;22:846-51. (Pubitemid 46911021)
51. Sookoian S, Fernández MA, Castaño G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study. World J Gastroenterol 2005;11:7560-3. (Pubitemid 43168416)
52. El-Demerdash E, Salam OM, El-Batran SA, Abdallah HM, Shaffie NM. Inhibition of the renin-angiotensin system attenuates the development of liver fibrosis and oxidative stress in rats. Clin Exp Pharmacol Physiol 2008;35:159-67.
53. Wang XP, Zhang R, Wu K, Wu L, Dong Y. Angiotensin II mediates acinar cell apoptosis during the development of rat pancreatic fibrosis by AT1R. Pancreas 2004;29:264-70. (Pubitemid 40228271)
54. Liu WB, Wang XP, Wu K, Zhang RL. Effects of angiotensin II receptor antagonist, losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells. World J Gastroenterol 2005;11:6489-94. (Pubitemid 43136886)
55. Morris GP, Beck PL, Herridege MS, Depew WT, Szewezuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803. (Pubitemid 19057602)
56. Latella G, Sferra R, Vetuschi A, et al. Prevention of colonic fibrosis by Boswellia and Scutellaria extracts in rats with colitis induced by 2,4,5-trinitrobenzene sulphonic acid. Eur J Clin Invest 2008;38:410-20. (Pubitemid 351712927)
57. Lawrance IC, Wu F, Leite AZA, et al. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kB. Gastroenterology 2003;125:1750-61. (Pubitemid 37500440)
58. Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-97. (Pubitemid 46127306)
59. Kumar R, Singh VP, Baker KM. The intracellular rennin-angiotensin system: Implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens 2008;17:168-73. (Pubitemid 351253042)
60. Hirasawa K, Sato Y, Hosoda Y, Yamamoto T, Hanai H. Immunohistochemical localization of angiotensin II receptor and local renin-angiotensin system in human colonic mucosa. J Histochem Cytochem 2002;50:275-82. (Pubitemid 34106766)
61. Sironi L, Nobili E, Giannella A, Gelosa P, Tremoli E. Anti-inflammatory properties of drugs acting on the renin-angiotensin system. Drugs Today 2005;41:609-22. (Pubitemid 41810476)
62. Ruiz-Ortega M, Ruperez M, Esteban VL,et al. Angiotensin II: A key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transpl 2006;21:16-20. (Pubitemid 43057101)
63. Inokuchi Y, Morohashi T, Kawana I, Nagashima Y, Kihara M, Umemura S. Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice. Gut 2005;54:349-56. (Pubitemid 40299090)
64. Roberts AB, Russo A, Felici A, Flanders KC. Smad3: A key player in pathogenetic mechanisms dependent on TGF-beta. Ann NY Acad Sci 2003;995:1-10. (Pubitemid 36706609)
65. Ma Y, Guan Q, Bai A, et al. Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis. Inflamm Bowel Dis 2010;16:1040-50.
66. Grainger DJ. Transforming growth factor beta and atherosclerosis: So far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004;24:399-404. (Pubitemid 38326130)
67. Lakos G, Tacagawa S, Chen SJ, et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004;165:203-17. (Pubitemid 38821828)
68. Zhao J, Shi W, Wang YL, et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002;282:L585-93. (Pubitemid 34654664)
69. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001;34:89-100. (Pubitemid 32591487)
70. Inazaki K, Kanamaru Y, Kojima Y, et al. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int 2004;66:597-604. (Pubitemid 38982001)
71. Fukasawa H, Yamamoto T, Togawa A, et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA 2004;101:8687-92. (Pubitemid 38745832)
72. Dooley S, Hamzavi J, Breitkopf K, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003;125:178-91. (Pubitemid 36799118)
73. Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: A putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002;99:3908-13. (Pubitemid 34252204)
74. Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999;104:5-11. (Pubitemid 29534339)
75. Wang B, Omar A, Angelovska T, et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am J Heart Cir Physiol 2007;293:H1282-90. (Pubitemid 47254231)
76. Latella G, Vetuschi A, Sferra R, et al. Smad3 loss confers resistance to the development of TNBS-induced colorectal fibrosis. Eur J Clin Invest 2009;39:145-56.
77. Daniel C. Blocking of angiotensin II is more than blocking of transforming growth factor-beta. Kidney Int 2008;74:551-3.
78. Hume GE, Fowler Ev, Lincoln D, et al. Angiotensinogen and transforming growth factor beta1: Novel genes in the pathogenesis of Crohn's disease. J Med Genet 2006;43:e51.